Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
Rhea-AI Summary
Nutriband (NASDAQ: NTRB / NTRBW) summarized key points from its Jan 24, 2026 annual shareholder meeting in Orlando. Highlights include board additions, AVERSA™ FENTANYL development progress, patent milestones, manufacturing scale-up, a Type C meeting with the US FDA, planned IND and HAL clinical trial work, ongoing Pocono Pharma sale activity, a FINRA complaint, and 2026 warrant expirations.
Notable specifics: exclusive development partnership with Kindeva, new patents in the US and Macao, collection of $30,000 in closing-extension penalties, and 91,0904 warrants expiring Oct 1, 2026 with $6.43 strike.
Positive
- Exclusive development partnership with Kindeva and shared development costs
- New US patent expanding abuse-deterrent transdermal IP protection
- Patent granted for AVERSA platform in Macao
- Completed commercial manufacturing scale-up with Kindeva
- Held Type C meeting with US FDA on CMC plans
Negative
- Full purchase price for Pocono Pharma not yet received as of Jan 24, 2026
- Only $30,000 collected toward closing-extension penalties so far
- 91,0904 warrants expire Oct 1, 2026, potential dilution if exercised
News Market Reaction
On the day this news was published, NTRBW declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While NTRB was down 3.83%, several biotech peers also traded lower (e.g., CVM -6.23%, OKYO -5.56%, XBIT -4.87%). The momentum scanner only flagged QNCX, down 6.33%, suggesting pressure in parts of the group but not a broad, synchronized sector move tied to this headline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | Shareholder letter | Positive | -3.0% | CEO summarized 2025 milestones and 2026 outlook including Pocono sale. |
| Dec 29 | Asset sale deal | Positive | +16.0% | Agreement to sell 90% of Pocono for <b>$5M</b> to fund AVERSA. |
| Dec 18 | LOI technology | Neutral | +3.0% | Non-binding LOI with Qvanta on advanced tech for abuse-deterrent R&D. |
| Dec 18 | Product positioning | Positive | +3.0% | Outlined AVERSA FENTANYL concept and projected peak U.S. sales. |
| Nov 24 | Conference appearance | Neutral | -2.1% | Announced Noble Capital conference presentation on growth story. |
Recent news has produced mixed reactions, with some positive corporate updates selling off and others rallying.
Over the last few months, Nutriband highlighted several milestones around AVERSA Fentanyl and corporate positioning. A $5M agreement to sell 90% of Pocono to EarthVision Bio and projected AVERSA U.S. peak sales of $80M–$200M were followed by a CEO shareholder letter reiterating 2025 progress and 2026 outlook. Other releases covered a technology LOI with Qvanta and conference participation. Today’s annual meeting summary, which updates on AVERSA development, Pocono sale status, and warrant overhang, continues that narrative of funding and advancing the lead program.
Market Pulse Summary
This announcement outlines Nutriband’s recent governance additions, concrete AVERSA™ FENTANYL milestones, and next steps toward an NDA, including HAL trial supplies and an IND filing. It also clarifies status of the Pocono sale and associated $10,000 weekly penalties, plus outstanding warrants that could bring in up to $5,856,112 if exercised before October 1, 2026. Investors may track progress on regulatory interactions, patent extension efforts toward 2046, and timing for the planned HAL clinical study.
Key Terms
investigational new drug (ind) application regulatory
human abuse liability (hal) clinical trial medical
human abuse liability (hal) clinical study medical
naked short selling financial
financial industry regulatory authority (finra) regulatory
transdermal medical
AI-generated analysis. Not financial advice.
ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida. Details and highlights may be found below.
Addition of Two New Directors
Allesandro Puddu
Alessandro Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory and financial reporting for industrial groups and listed companies.
He advises companies on tax and corporate matters, company valuations, extraordinary corporate transactions and IAS/IFRS reporting, including consolidated financial statements. He has supported the design and implementation of accounting and administrative procedures and regularly serves as statutory auditor and member of statutory boards of Italian companies.
He currently serves as Group Internal Auditor for a company listed on the STAR segment of the Italian Stock Exchange, overseeing internal control and audit activities, including those related to the Group’s United States subsidiaries. At the beginning of his career, he worked at PricewaterhouseCoopers as a Senior Auditor, reviewing Italian and multinational companies operating in various industrial sectors, including the pharmaceutical sector, and coordinating audit teams across multiple jurisdictions.
Alessandro Puddu is enrolled in the Italian Register of Chartered Accountants (Dottori Commercialisti), the Register of Statutory Auditors held by the Italian Ministry of Economy and Finance, and the Register of Crisis & Insolvency Practitioners, and holds a Master’s Degree in Economics and Management.
Viorica Carlig
Viorica Carlig is a senior executive with over a decade of leadership experience across service-based companies. She currently provides executive and strategic oversight for multiple multinational organizations, leading operations, governance, compliance, budgeting, and growth initiatives in complex regulatory environments. With a background spanning business administration, law, and economics—including a Ph.D. in Economics—Viorica combines strong commercial judgment with rigorous operational and risk management expertise. Earlier in her career, she practiced commercial and corporate law as a member of the Bucharest Bar, advising companies on contracts, governance, and regulatory compliance. She is a multilingual leader experienced in managing diverse teams and stakeholders across Europe and beyond.
2025 AVERSA™ FENTANYL Development Summary
- Strengthened collaboration with Kindeva for AVERSA™ FENTANYL through an exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments
- Granted patent protecting its AVERSA™ abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China
- Completed commercial manufacturing process scale-up with partner Kindeva for Aversa™ Fentanyl
- Issued new US patent which further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products
- Held Type C meeting with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL through commercialization
- Filed a new provisional patent application with the U.S. Patent and Trademark Office (USPTO) covering improved aversive formulations and coating application methods to enhance the abuse deterrent properties and further strengthen Nutriband’s intellectual property protection for its AVERSA™ technology
- Initiated development of the worldwide commercial brand name and visual identity for AVERSA™ FENTANYL with Brand Institute, Inc.
2026 AVERSA™ FENTANYL Focus on Development Towards NDA Filing
- File nonprovisional patent application to potentially extend patent protection of AVERSA™ technology-based products to 2046
- Manufacture clinical supplies for the Human Abuse Liability (HAL) clinical trial
- File Investigational New Drug (IND) application with the US FDA
- Initiate Human Abuse Liability (HAL) clinical study
EarthVision Bio Purchase of Pocono Pharma
The full purchase price and closing for the proposed sale of our Pocono subsidiary has not been received as of the shareholder meeting on Jan 24, 2026. However, the Company is collecting on the agreed nonrefundable
Company Complaint Filed with FINRA
The Company, has filed a complaint with the Financial Industry Regulatory Authority (FINRA) on behalf of our shareholders to look into suspected naked short selling. The information was collected and prepared with a specialist analyst in the area of naked short selling.
Warrant Expiration in 2026
The Company is reminding shareholders that the warrants issued in our uplisting to NASDAQ on October 1, 2021 will expire on October 1, 2026. Currently there are 91,0904 warrants set to expire with a strike price of
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What did Nutriband (NTRB) announce about AVERSA™ FENTANYL development on Jan 30, 2026?
Has Nutriband filed any regulatory submissions for AVERSA™ FENTANYL and when will clinical HAL work start?
What is the status of the Pocono Pharma sale announced by Nutriband (NTRB)?
What patents and IP protections did Nutriband report for AVERSA™ as of Jan 2026?
What should shareholders of Nutriband (NTRB) know about the 2026 warrant expirations?
